Novartis AG
HealthcareNYSE:NVS · New York Stock Exchange
-$0.45 today
Vol 0.75M · Avg 1.64M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $6.9B |
| Short-term Investments | $100.0M |
| Receivables | $9.6B |
| Inventory | $6.3B |
| Other Current | $3.7B |
| Total Current Assets | $26.6B |
| PP&E (Net) | $12.2B |
| Goodwill | $26.8B |
| Intangible Assets | $40.2B |
| Long-term Investments | $2.4B |
| Tax Assets | $5.2B |
| Other Non-current | $5.0B |
| Total Non-current Assets | $91.9B |
| Total Assets | $118.5B |
Analysis
Selected assets total $118.5B for Latest. The largest visible component is Intangible Assets at $40.2B, about 33.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.4B -0.2% | $11.5B -14.4% | $13.4B +78.2% | $7.5B -39.4% | $12.4B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $155.0M -91.8% | $1.9B +232.5% | $569.0M -94.9% | $11.1B -29.3% | $15.7B | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $10.9B +33.2% | $8.2B -12.4% | $9.4B -5.2% | $9.9B +2.8% | $9.6B | $533.8M | $399.4M | -$1.7B |
| Inventory | $6.3B +9.5% | $5.7B -3.2% | $5.9B -17.6% | $7.2B +7.6% | $6.7B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $514.0M -64.2% | $1.4B +207.7% | $466.0M +47.9% | $315.0M +45.8% | $216.0M | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $30.5B +2.5% | $29.7B -2.5% | $30.5B -17.4% | $36.9B -19.3% | $45.7B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $12.4B +13.6% | $10.9B -0.5% | $10.9B -10.4% | $12.2B -7.0% | $13.1B | $1.2B | $1.5B | $687.8M |
| Goodwill | $25.6B +3.3% | $24.8B +6.1% | $23.3B -20.3% | $29.3B -1.0% | $29.6B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $29.4B +9.3% | $26.9B +0.1% | $26.9B -15.1% | $31.6B -7.4% | $34.2B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $2.3B +104.3% | $1.1B -38.3% | $1.8B +13.8% | $1.6B -29.2% | $2.3B | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $10.1B +130.7% | $4.4B +1.2% | $4.3B +15.2% | $3.7B -0.1% | $3.7B | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $5.4B +20.1% | $4.5B +106.5% | $2.2B +6.1% | $2.1B -35.3% | $3.2B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $85.1B +17.3% | $72.5B +4.4% | $69.5B -13.8% | $80.5B -6.4% | $86.1B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $115.6B +13.0% | $102.2B +2.3% | $99.9B -14.9% | $117.5B -10.9% | $131.8B | $13.3B | $11.9B | $10.6B |
| Account Payables | $4.5B -2.5% | $4.6B -7.2% | $4.9B -4.3% | $5.1B -7.3% | $5.6B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $5.8B -28.5% | $8.1B +33.0% | $6.1B +3.5% | $5.9B -5.6% | $6.2B | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $2.6B +16.0% | $2.2B -7.6% | $2.4B -28.5% | $3.4B +11.0% | $3.0B | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 -100.0% | $127.0M +29.6% | $98.0M -20.3% | $123.0M +0.0% | $123.0M | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $12.8B +23.4% | $10.4B +5.6% | $9.8B -12.2% | $11.2B -9.9% | $12.4B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $27.3B -4.9% | $28.7B +8.7% | $26.4B -7.9% | $28.7B -5.1% | $30.2B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $29.6B +38.5% | $21.4B +15.9% | $18.4B -8.9% | $20.2B -11.6% | $22.9B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $8.0B +231.4% | $2.4B +7.6% | $2.2B -16.3% | $2.7B -12.5% | $3.1B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $2.5B -39.2% | $4.1B -9.9% | $4.5B -7.8% | $4.9B -20.5% | $6.2B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $41.7B +41.8% | $29.4B +9.8% | $26.8B -8.7% | $29.4B -13.0% | $33.8B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $69.0B +18.8% | $58.1B +9.3% | $53.2B -8.3% | $58.0B -9.3% | $64.0B | $14.7B | $3.7B | $9.6B |
| Common Stock | $766.0M -3.4% | $793.0M -3.9% | $825.0M -7.3% | $890.0M -1.2% | $901.0M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $44.7B -4.0% | $46.6B -6.2% | $49.6B -21.9% | $63.5B -10.5% | $71.0B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $694.0M +121.3% | -$3.3B +13.6% | -$3.8B +24.6% | -$5.0B -19.3% | -$4.2B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $419.0M +423.8% | $80.0M -3.6% | $83.0M +2.5% | $81.0M -51.5% | $167.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $46.5B +5.5% | $44.1B -5.6% | $46.8B -21.3% | $59.4B -12.4% | $67.8B | $9.1B | $7.7B | $3.3B |
| Total Debt | $37.0B +18.5% | $31.3B +18.6% | $26.3B -5.6% | $27.9B -10.0% | $31.0B | $724.2M | $410.6M | $399.4M |
| Net Debt | $25.6B +29.3% | $19.8B +52.8% | $13.0B -36.5% | $20.4B +9.5% | $18.6B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Eli Lilly and Company
NYSE:LLY
$1.08T
Johnson & Johnson
NYSE:JNJ
$578.23B
AbbVie Inc.
NYSE:ABBV
$401.62B
Roche Holding AG
RHHBY
$332.93B
Merck & Co., Inc.
NYSE:MRK
$296.47B
AstraZeneca PLC
NYSE:AZN
$278.74B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.61B
Pfizer Inc.
NYSE:PFE
$149.30B
Bristol-Myers Squibb Company
NYSE:BMY
$116.72B
GSK plc
NYSE:GSK
$106.61B
Sanofi
NASDAQ:SNY
$106.50B
Bayer AG
BAYRY
$41.07B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does NVS have?
Novartis AG (NVS) reported $11.44B in cash and equivalents in fiscal 2025.
How much debt does NVS carry?
Novartis AG (NVS) reported $37.03B of total debt, with net debt of $25.60B.
Explore More
Continue the stock analysis
Jump to another research area for this company.